𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rhinorrhea in Parkinson's disease: A consecutive multicenter study in Japan

✍ Scribed by Kano, Osamu; Yoshioka, Masayuki; Nagayama, Hiroshi; Hamada, Shinsuke; Maeda, Tetsuya; Hasegawa, Takafumi; Kadowaki, Taro; Sengoku, Renpei; Terashi, Hiroo; Hatano, Taku; Nomoto, Nobuatsu; Inoue, Manabu; Shimura, Hideki; Takahashi, Tatsuya; Uchiyama, Tsuyoshi; Watanabe, Hirohisa; Kaneko, Satoshi; Takahashi, Tetsuya; Baba, Yasuhiko; Kubo, Shin-ichiro


Book ID
124132957
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
259 KB
Volume
343
Category
Article
ISSN
0022-510X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Rhinorrhea is increased in Parkinson's d
✍ Joseph H. Friedman; Melissa M. Amick πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 54 KB

## Abstract We have observed that rhinorrhea is increased in people with Parkinson's disease (PD) but only a single publication supports this. We performed two separate case control studies to assess the prevalence of rhinorrhea in PD in Rhode Island. One was cross‐sectional and the other in consec

Camptocormia in Japanese patients with P
✍ Morinobu Seki; Kazushi Takahashi; Atsuo Koto; Ban Mihara; Yoko Morita; Kazuo Iso πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 264 KB πŸ‘ 1 views

## Abstract ## Objective: The aim of this work was to investigate the prevalence of camptocormia and the clinical characteristics of patients with camptocormia in a large population of PD patients. ## Background: Although camptocormia has been recognized as a prominent phenomenon in PD, the prev

Pergolide compared with bromocriptine in
✍ Dr. G. Pezzoli; E. Martignoni; C. Pacchetti; V. A. Angeleri; P. Lamberti; A. Mur πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 511 KB

## Abstract We compared the efficacy and safety of pergolide and bromocriptine in 57 patients with Parkinson's disease (PD) with a declining response to levodopa therapy in a single‐blind, crossover study. Patients were placed randomly on the sequence bromocriptine‐pergolide (12 + 12 weeks) or vice